Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa.
This report describes the analysis of a novel mutant human factor IX protein from a patient with hemophilia B (factor IX activity <1%; factor IX antigen 45%). Enzymatic amplification of all eight exons of the factor IX gene followed by direct sequence analysis reveals a single nucleotide change (a guanine --> adenine transition) in exon 2 at nucleotide 6409 which results in a glycine --> arginine substitution at amino acid 12 in the gamma-carboxyglutamic acid rich (Gla) domain of the mature protein. Factor IX was isolated by immunoaffinity chromatography from plasma obtained from the proband. The purified protein is indistinguishable from normal factor IX by polyacrylamide gel electrophoresis. Characterization of the variant in purified component assays reveals that it is activated normally by its physiologic activator factor XIa, but its phospholipid-dependent activation by the factor VIIa-tissue factor complex is diminished. In the presence of phospholipid and 5 mM Ca2+, the activities of variant and normal plasma-derived factor IX are similar; however, in the presence of activated factor VIIIa (intrinsic tenase complex), the normal augmentation of the cleavage of the specific substrate of factor IX, factor X, is not observed. The determination of the association constants for normal and variant factor IXa with factor VIIIa shows that the affinity of the activated variant factor IX for the cofactor factor VIIIa is 172-fold lower than normal. Competition studies using active site-inactivated factor IXas in the intrinsic tenase complex confirm that the defect in the variant protein is in its binding to factor VIIIa. We conclude that the structural integrity of the Gla domain of human factor IX is critical for the normal binding of factor IXa to factor VIIIa in the intrinsic tenase complex. In addition, a glycine at amino acid 12 is necessary for normal activation of factor IX by the factor VIIa-tissue factor complex.
Larson
P J
PJ
Department of Pediatrics, University of Pennsylvania, Philadelphia, 19104, USA.
Stanfield-Oakley
S A
SA
VanDusen
W J
WJ
Kasper
C K
CK
Smith
K J
KJ
Monroe
D M
DM
High
K A
KA
D000225:Adenine; D000595:Amino Acid Sequence; D001120:Arginine; D001483:Base Sequence; D001665:Binding Sites; D004247:DNA / Q000097:blood; D004252:DNA Mutational Analysis; D005091:Exons; D005164:Factor IX / Q000737:chemistry; D015949:Factor IXa / Q000737:chemistry* / Q000378:metabolism*; D015944:Factor VIIIa / Q000378:metabolism*; D005170:Factor X / Q000737:chemistry / Q000235:genetics* / Q000302:isolation & purification; D005998:Glycine; D006147:Guanine; D002836:Hemophilia B / Q000097:blood / Q000235:genetics*; D006801:Humans; D007700:Kinetics; D008433:Mathematics; D008962:Models, Theoretical; D008969:Molecular Sequence Data; D017354:Point Mutation; D011517:Prothrombin Time; D014227:Triazines
D014227:Triazines; C053507:4-azido-7-phenylpyrazolo-(1,5a)-1,3,5-triazine; D006147:Guanine; D015944:Factor VIIIa; D005164:Factor IX; D005170:Factor X; D004247:DNA; D001120:Arginine; D015949:Factor IXa; D000225:Adenine; D005998:Glycine